Gonadorelin

Gonadorelin is a synthetic decapeptide (molecular formula C55H75N17O13) with an amino acid sequence identical to endogenous gonadotropin-releasing hormone (GnRH), the neuropeptide secreted in intermittent pulses by the hypothalamus.

It binds to GnRH receptors on gonadotroph cells of the anterior pituitary, activating intracellular signaling that drives synthesis and release of both luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

The biological response is critically pattern-dependent. Pulsatile delivery — mimicking the physiological 90-to-120-minute intermittent secretory rhythm — sustains receptor sensitivity and maintains gonadotropin output. Continuous, non-pulsatile stimulation instead downregulates GnRH receptors and paradoxically suppresses LH and FSH secretion; this is the mechanism by which long-acting GnRH agonists such as leuprolide achieve gonadal suppression, and it distinguishes gonadorelin's therapeutic effect from that drug class.

In males, LH acts on testicular Leydig cells to drive testosterone biosynthesis; FSH supports Sertoli cells and spermatogenesis. In females, the GnRH-driven LH surge triggers ovulation, while FSH governs follicular maturation. Gonadorelin engages the full HPG axis rather than bypassing it.

Plasma half-life is 2 to 10 minutes (distribution phase) and 10 to 40 minutes (terminal phase); the peptide is cleared primarily by enzymatic hydrolysis into smaller fragments.

Gonadorelin was FDA-approved under two discontinued branded products: Factrel (hydrochloride salt, for diagnostic pituitary stimulation testing) and Lutrepulse (acetate salt, for ovulation induction via pulsatile pump). No commercially approved human formulation exists in the United States as of 2026; compounded versions remain available through licensed pharmacies under applicable regulations.

The most robust evidence base is in functional hypothalamic amenorrhea (FHA). A 25-year retrospective cohort (Quaas et al., J Assist Reprod Genet, 2022; n=66 patients, 82 treatment episodes, 212 ovulation induction cycles) using 10 µg per 90-minute subcutaneous pulse documented a per-cycle ovulation rate of 96%, a clinical pregnancy rate of 74.4% per treatment episode, and a live birth rate of 65.9%. Monofollicular ovulation occurred in 75% of cycles, the multiple pregnancy rate was 1.6%, and no severe adverse events were reported.

In male congenital hypogonadotropic hypogonadism (CHH), a systematic review and meta-analysis (Wei et al., World J Men's Health, 2021; 7 studies, n=420 patients) compared pulsatile GnRH with combination gonadotropin therapy. Pulsatile GnRH produced earlier onset of spermatogenesis (5.3 months sooner; p=0.004) and greater testicular volume increases (p=0.01), with no statistically significant differences in final spermatogenesis rates, sperm concentration, or pregnancy rates. A retrospective series in adult male CHH (Jiang et al., Transl Androl Urol, 2025; n=54, mean age 22.8 years) using 10 µg/90-min pulses documented serum testosterone rising from 48 to 381 ng/dL over two years, testicular volume from 3.19 to 9.73 mL, and spermatogenesis achieved in 79.4% of evaluable patients at a mean of 6.5 months.

The widely used off-label application as a testosterone replacement therapy (TRT) adjunct to preserve testicular volume and spermatogenesis during exogenous testosterone administration lacks published RCT support; evidence for this indication is limited to expert opinion and anecdotal clinical reports.

Typical dosage: 100 mcg (as prescribed).

Dosing varies substantially by indication. All values below are drawn from published literature and historical prescribing information. This content is educational only and does not constitute medical advice; consult a licensed healthcare provider before use.

Pituitary function assessment (GnRH stimulation test, historical Factrel regimen): A single dose of 100 µg administered intravenously or subcutaneously. Serum LH and FSH are drawn at baseline and at 15, 30, 45, 60, and 120 minutes after injection. In normal adult males, mean peak LH is approximately 60 mIU/mL at around 34 minutes. In women during the early follicular phase (days 1-7), mean peak LH is approximately 68 mIU/mL at around 72 minutes.

Ovulation induction in hypothalamic amenorrhea (historical Lutrepulse regimen and investigational practice): 10 to 20 µg per pulse delivered subcutaneously every 90 minutes via a programmable ambulatory infusion pump, with serial ultrasound monitoring of follicular development.

Pulsatile therapy for hypogonadotropic hypogonadism (male or female): Typically 5 to 15 µg per pulse every 90 to 120 minutes via subcutaneous infusion pump, titrated based on serum LH, FSH, testosterone, and testicular volume response. Published CHH series most commonly begin at 10 µg per 90-minute pulse.

Off-label compounded use during testosterone replacement therapy (anecdotal; no published dose-finding studies): Reported clinic protocols use 100 to 500 µg subcutaneously, administered two to three times weekly.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

In congenital hypogonadotropic hypogonadism, pulsatile gonadorelin has been studied sequentially or concurrently with gonadotropin therapy (hCG combined with hMG or recombinant FSH). Some centers prime testicular volume with gonadotropins first before transitioning to pulsatile GnRH for spermatogenesis optimization; the Wei et al. meta-analysis and other published series have also evaluated pulsatile GnRH as a salvage approach for patients who respond inadequately to gonadotropin therapy alone.

In the off-label testosterone replacement therapy (TRT) setting, compounded gonadorelin is commonly combined with exogenous testosterone (typically cypionate or enanthate) with the stated rationale of maintaining endogenous LH and FSH stimulation to preserve testicular size and spermatogenesis. It gained traction in this role following regulatory changes that restricted compounded human chorionic gonadotropin (hCG), which had previously been the standard adjunct for the same purpose. Some clinic protocols additionally incorporate an aromatase inhibitor (anastrozole) to manage estrogen conversion, or clomiphene citrate as an alternative or adjunctive agent.

Evidence for gonadorelin-containing combination protocols in the TRT context is anecdotal and clinic-based; no published randomized controlled trial has directly evaluated these regimens.

Gonadorelin is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Headache, nausea possible

At single diagnostic doses (100 µg), gonadorelin is generally well tolerated. Systemic effects reported rarely include headache, light-headedness, nausea, abdominal discomfort, and flushing. Subcutaneous injection may produce local swelling, pain, or pruritus at the administration site; local and generalized skin rash have been noted with chronic subcutaneous administration.

Hypersensitivity reactions — including bronchospasm, tachycardia, urticaria, and anaphylaxis — are rare but documented with chronic or high-dose administration. No hypersensitivity reactions attributable to a single 100 µg diagnostic dose have been reported in the prescribing literature. Antibody formation against gonadorelin may develop with prolonged high-dose therapy and can attenuate clinical response over time.

Pituitary apoplexy (hemorrhagic or ischemic infarction of the pituitary gland) is a rare but serious adverse event, primarily described in patients with pre-existing pituitary adenomas. It may occur days after a stimulation test and presents with sudden severe headache, vomiting, visual disturbance, and ophthalmoplegia. Paradoxical suppression of gonadotropin release can result from high-dose non-pulsatile administration due to GnRH receptor downregulation.

Contraindications include known hypersensitivity to gonadorelin. Concurrent use of androgens, estrogens, progestins, glucocorticoids, or digoxin may suppress the LH response; spironolactone and dopamine antagonists (including phenothiazines) may alter gonadotropin levels and confound testing. A confirmed or suspected pituitary tumor is a relative contraindication except under specialist supervision.

Gonadorelin is Pregnancy Category B based on animal studies with no evidence of fetal harm; its excretion in human breast milk is unknown, and caution is advised for nursing mothers.